![Thomas Leggett](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Leggett
Finanzdirektor/CFO bei
STOKE THERAPEUTICS, INC.
Vermögen: 465 444 $ am 31.05.2026
Profil
Thomas E.
Leggett currently serves as Chief Financial & Accounting Officer at Stoke Therapeutics, Inc. since 2024.
He is an Independent Director at Research Alliance Corp.
II and an Independent Non-Executive Director at Clover Biopharmaceuticals Ltd., both positions held since 2021.
Formerly, Mr. Leggett was Chief Financial Officer at Affinia Therapeutics, Inc. from 2021 to 2024, Chief Financial & Accounting Officer at Black Diamond Therapeutics, Inc. from 2019 to 2021, Chief Financial Officer & Senior VP-Finance at Axcella Health, Inc. from 2017 to 2019, Treasurer & Head-Finance Business Development at Purdue Pharma LP in 2016, and Executive Director at UBS Securities LLC from 2009 to 2015.
Education includes an undergraduate degree from The Trustees of Columbia University in The City of New York in 1999 and an MBA from The Wharton School of the University of Pennsylvania in 2004.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
STOKE THERAPEUTICS, INC. 0,02 % | 31.03.2026 | 10.172 ( 0,02 % ) | 314 417 $ | 31.05.2026 |
| 02.04.2026 | 607.000 ( 0,05 % ) | 151 028 $ | 31.05.2026 |
Aktive Positionen von Thomas Leggett
| Unternehmen | Position | Beginn |
|---|---|---|
| RESEARCH ALLIANCE CORP. II | Direktor/Vorstandsmitglied | 01.02.2021 |
| CLOVER BIOPHARMACEUTICALS, LTD. | Direktor/Vorstandsmitglied | 19.04.2021 |
| STOKE THERAPEUTICS, INC. | Finanzdirektor/CFO | 07.05.2024 |
Ehemalige bekannte Positionen von Thomas Leggett
| Unternehmen | Position | Ende |
|---|---|---|
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Finanzdirektor/CFO | 30.04.2024 |
| BLACK DIAMOND THERAPEUTICS, INC. | Finanzdirektor/CFO | 16.11.2021 |
| AXCA HEALPAR | Finanzdirektor/CFO | 30.08.2019 |
Purdue Pharma LP
 Purdue Pharma LP Medical DistributorsDistribution Services Distributes medicines | Treasurer | 01.12.2016 |
UBS Securities LLC
 UBS Securities LLC Investment Banks/BrokersFinance Provides brokerage services | Direktor/Vorstandsmitglied | 01.05.2015 |
Ausbildung von Thomas Leggett
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
99
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
UBS Securities LLC
UBS Securities LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Purdue Pharma LP
Purdue Pharma LP Medical DistributorsDistribution Services Distributes medicines | Distribution Services |
Axcella Health, Inc.
 Axcella Health, Inc. BiotechnologyHealth Technology Provides first-in-class precision therapeutic solutions to diseases with a focus on restoring amino acid biology | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stoke Therapeutics, Inc.
 Stoke Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company focused on the development of first-in-class therapeutics that selectively increase gene expression to treat genetic diseases | Health Technology |
Black Diamond Therapeutics, Inc.
 Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Health Technology |
Research Alliance Corp. II
 Research Alliance Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
Clover Biopharmaceuticals Ltd.
 Clover Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
Wählen Sie MarketScreener 
